Methylation status of RB1 promoter in indian retinoblastoma patients

Cancer Biology and Therapy

Volumn 3, Issue 2, 2004, Pages 184-187

  Joseph, Biju ^a   Mamatha, Gandra ^a   Raman, Gayathree ^a   Shanmugam, Mahesh Palanivelu ^b   Kumaramanickavel, Govindasamy ^a,c  

^a Vision Resarch Foundation   (India)

^b MEDICAL RESEARCH FOUNDATION   (India)

^c VISION RESEARCH FOUNDATION   (India)

Author keywords

Bisulfite modification; Methylation; Methylation specific PCR; Rb1 promoter

Indexed keywords

ARTICLE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; FAMILY; FEMALE; GENETIC COUNSELING; HUMAN; INDIA; INDIAN; INFANT; MALE; METHYLATION; MOLECULAR MECHANICS; POLYMERASE CHAIN REACTION; PROMOTER REGION; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE; DNA METHYLATION; GENETICS; METABOLISM; PATHOLOGY; PRESCHOOL CHILD;

DNA; RETINOBLASTOMA PROTEIN;

CHILD, PRESCHOOL; CPG ISLANDS; DNA METHYLATION; DNA, NEOPLASM; FEMALE; HUMANS; INDIA; INFANT; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGIONS (GENETICS); RETINOBLASTOMA; RETINOBLASTOMA PROTEIN;

EID: 16544371972     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.3.2.620     Document Type: Article

References (36)

1. Ohtani-Fujita T, Aoike A, Osifchin NE, Robbins PD, Sakai T. CpG methylation inactivates the promoter activity of the human Retinoblastoma tumour-suppressor gene. Oncogene 1993; 8:1063-7.
2. Gregor V, Passarge E, Hopping W, Messsmer E, Horstemke B. Epigenetic changes may contribute to the formation and spontaneous regression of Retinoblastoma. Hum Genet 1989; 83:155-8.
3. Gregor V, Debus N, Lohmann D, Hopping W, Passarge E, Horsthemke B. Frequency and parental origin of hypermethylated RB1 alleles in retinoblastoma. Hum Genet 1994; 94:491-6.
4. Herman JG, Graff J R, Myohanen S, Nelkin BD, Baylin SB. A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6.
5. Dobrovic A, Simpfendorfer D. Methylation of the BRCA1 gene in sporadic breast cancer. Cancer Res 1997; 16:3347-50.
6. Hiraguri S, Godfrey T, Nakamura H, Graff J, Collins C, Shayesteh L, et al. Mechanisms of inactivation of E-cadherin in breast cancer cell lines. Cancer Res 1998; 58:1972-7.
7. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG islands links aging and neoplasia in human colon. Nat Genet 1994; 7:536-40.
8. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X. Aberrant CpG island methylation has nonrandom and tumour-type specific patterns. Nat Genet 2000; 24:132-8.
9. Yan PS, Chen C, Shi H, Rahmatpanah F, Wein SH, Caldwell CW, et al. Dissecting complex epigenetic alterations in breast cancer using cpG island microarrays. Cancer Res 2001; 61:8375-80.
10. Nakamura M, Yonekawa Y, Kleihaues P, Ohgaki H. Promoter hypermethylation of the RB1 gene in glioblastomas. Laboratory Investigation 2001; 81:77-82.
11. Salem C, Liang G., Tsai YC, Coulter J, Knowles MA, Feng A. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000; 60:2473-6.
12. Herman JG, Latif F, Weng Y, Lerman MI, Zbar B, Liu S, et al. Silencing of the VHL tumour suppressor gene by DNA methylation in renal cell carcinoma. Proc Natl Acad Sci USA 1994; 91:9700-4.
13. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 1998; 72:141-96.
14. INK2A characterize the major types of hematological malignancies. Cancer Res 1997; 57:837-41.
15. Esteller M, Silva JM, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E, et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumours. J Natl Cancer Inst 2000; 92:564-9.
16. Baylin SB, Herman JG DNA methylation in tumourigenesis. Trends genet 2000; 16:168-74.
17. 6-methy guanine-DNA methyl transferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumourigenesis. Cancer Res 2000; 60:2368-71.
18. 6- methylguanine-DNA methyltransferase in retinoblastoma tissues. Invest Ophtahmol Vis Sci 2002; 43:1344-9.
19. Edmunds SC, Kelsell DP, Hungerford JI, Cree IA. Mutational analysis of selected genes in the TGFβ, Wnt, pRb, and p53 pathway in primary uveal melanomas. Invest Ophthalmol Vis Sci 2002; 43:2845-51.
20. Narayan G, Arias-Pulido H, Koul S, Vargas H, Zhang FF, Villella J. Frequent hypermethylation of CDHI, DAPK, RARB and HICI genes in carcinoma of cervix uteri: Its relationship to clinical outcome. http://www.molecular-cancer. com/content/2/1/24.
21. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 2000; 60:1211-6.
22. Sakai T, Toguchida J, Ohtani N, Yandell DW, Rapaport JM, Dryja TP. Allele-specific hypermethylation of the Retinoblastoma tumour suppressor gene. Am J Hum Genet 1991; 48:880-8.
23. Strirzaker C, Millar S, Paul CL, Warnecke PM, Harrison J, Vincent P, et al. Extensive DNA methylation spanning the RB promoter in Retinoblastoma tumours. Cancer Res 1997; 57:2229-37.
24. Wong IHN. Methylation profiling of human cancers in blood: Molecular monitoring and prognostication. International journal of oncology 2001; 19:1319-24.
25. Jones C, Booth C, Rita D, Jasmines L, Brandt B, Newlan A, et al. Bilateral retinoblastoma in a male patient with an X: 13 translocation: Evidence for silencing of the RB1 gene by the spreading of X inactivation. Am J Hum Genet 1997; 60:1558-62.
26. Wolff R, Gemmil R. Purifying and analyzing genomic DNA. In: Bruce B, Green ED, Sueklaplholz, Myeres RM, Roskans J, eds. Genome Analysis-A laboratory manual. CSHL Press, 1998.
27. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, et al. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc Natl Acad Sci USA 1992; 89:1827-31.
28. Zeschnigk M, Lohmann D, Horsthemke B. A PCR test for the detection of hypermethylated alleles at the retinoblastoma locus. J Med Genet 1997; 36:793-4.
29. Choy KW, Pang CP, Yu CBO, Wong HL, Ng JSK, Fan DSP, et al. Loss of heterozygosity and mutations are the major mechanisms of RB1 gene inactivation in Chinese patients with sporadic retinoblastoma. Hum Mutat 2002; 20:408.
30. Lohmann DR, Gerick M, Brandt B, Oelschlager U, Lorenz B, Passarge E, et al. Constitutional RB1 mutations in patients with isolated unilateral retinoblastoma. Am J Hum Genet 1997; 61:282-94.
31. Vogel F. Genetics of retinoblastoma. Hum Genet 1979; 52:1-54.
32. Strathdee, Brown R. Aberrant DNA methylation in cancer: potential clinical interventions. Exp Rev Mol Med 2002; http://www-ermm.cbcu.cam.ac.uk/ 02004222h.htm
33. Bovenzi V, Le NLO, Cote S, Sinnett D, Momparler LF, Momparler RL. DNA methylation of the retinoic acid receptor beta gene in breast cancer and possible therapeutic role of 5′-aza -2′-deoxy cytidine. Anticancer drugs 1999; 10:471-6.
34. Herman JG, Latif F, Weng Y, Lerman MI, Zhar B, Liu S, et al. Silencing of the VHL tumour suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994; 91:9700-4.
35. Thiabolt A, Figg WD, Bergan RC, Lush RM, Myers CE, Tompkins A, et al. A phase II study of 5-aza-2′-deoxy cytidine in hormone independent metastatic (D2) prostate cancer. Tumouri 1998; 84:87-9.
36. Mareel M, Bracke M, Van Roy F. Cancer metastasis: Negative regulation by an invasion-suppressor complex. Cancer Detect Prev 1995; 19:451-64.